Literature DB >> 19899421

Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.

M Takano1, T Yoshikawa, T Yoshokawa, M Kato, S Aida, T Goto, K Furuya, Y Kikuchi.   

Abstract

The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma. Clear cell carcinoma (CCC) is mostly derived from the ovary and often associated with endometriosis. We describe the clinicopathologic features of two cases diagnosed as CCC of the peritoneum origin. Case 1, a 53-year-old woman, presented with upper abdominal and pelvic tumors. Case 2, a 66-year-old woman, presented with massive ascites and abdominal tumor. The ovaries and uterine endometrium of these cases were not affected, and the tumors were diagnosed as Stage IIIc CCC of the peritoneum origin. Pathologically, endometriosis was not observed in either case. Adjuvant chemotherapy using irinotecan and cisplatin was effective in one case. The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19899421

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

Review 1.  Clear cell adenocarcinoma of the peritoneum: a case report and literature review.

Authors:  Naoya Shigeta; Kiyoshi Yoshino; Shinya Matsuzaki; Eiichi Morii; Yutaka Ueda; Tadashi Kimura
Journal:  J Ovarian Res       Date:  2014-10-02       Impact factor: 4.234

2.  Primary diaphragmatic clear cell carcinoma associated with endometriosis: A case report and literature review.

Authors:  Mitsuru Matsuki; Isao Numoto; Takefumi Hamakawa; Kazunari Ishii; Takaaki Chikugo
Journal:  Gynecol Oncol Rep       Date:  2021-02-19

3.  Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report.

Authors:  Skyler B Johnson; Joann I Prisciandaro; Jessica Zhou; Scott W Hadley; R Kevin Reynolds; Shruti Jolly
Journal:  J Appl Clin Med Phys       Date:  2014-01-06       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.